Circulating Histone Profiles Discriminate Heart Failure Patients With Preserved Versus Reduced Ejection Fraction
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652079%3A_____%2F25%3A00644785" target="_blank" >RIV/86652079:_____/25:00644785 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.sciencedirect.com/science/article/pii/S107191642400808X" target="_blank" >https://www.sciencedirect.com/science/article/pii/S107191642400808X</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Circulating Histone Profiles Discriminate Heart Failure Patients With Preserved Versus Reduced Ejection Fraction
Popis výsledku v původním jazyce
Heart failure (HF) is a heterogeneous disease, encompassing a wide range of symptoms. Treatment for HF patients with reduced ejection fraction (HFrEF) lack efficacy for HF patients with preserved ejection fraction (HFpEF). Moreover, HFpEF and HFrEF present different etiologies and comorbidities. The diagnosis of HFpEF remains a challenge, with score-based algorithms showing varying diagnostic performance. Furthermore, levels of BNP and/or NT-proBNP are below detection threshold in approximately 20% of the HFpEF patients. Circulating histones, released in the blood upon cell death, recently emerged as robust biomarkers of inflammation and stroke, but their diagnostic role in HF remains unknown.
Název v anglickém jazyce
Circulating Histone Profiles Discriminate Heart Failure Patients With Preserved Versus Reduced Ejection Fraction
Popis výsledku anglicky
Heart failure (HF) is a heterogeneous disease, encompassing a wide range of symptoms. Treatment for HF patients with reduced ejection fraction (HFrEF) lack efficacy for HF patients with preserved ejection fraction (HFpEF). Moreover, HFpEF and HFrEF present different etiologies and comorbidities. The diagnosis of HFpEF remains a challenge, with score-based algorithms showing varying diagnostic performance. Furthermore, levels of BNP and/or NT-proBNP are below detection threshold in approximately 20% of the HFpEF patients. Circulating histones, released in the blood upon cell death, recently emerged as robust biomarkers of inflammation and stroke, but their diagnostic role in HF remains unknown.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů